SCHEMBL17397188

SCHEMBL17397188

CC(=O)c1cc2cccc(C)n2c(=O)c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.41
PIK3CB P42338 2/20 0.41
PIK3CA P42336 1/20 0.41
KDM4E B2RXH2 2/20 0.39
BRD4 O60885 2/20 0.39
TSHR P16473 1/20 0.36
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
EGFR P00533 1/20 0.35
MAPT P10636 2/20 0.35
HSD11B1 P28845 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
POLB P06746 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17397300 0.90 PIK3CD (0.42) PIK3CDPIK3CBPIK3CAKDM4ETSHR
SCHEMBL17397207 0.87 PTGS2 (0.37) PIK3CDPIK3CBPIK3CAKDM4EALDH1A1
SCHEMBL17397262 0.83 KDM4E (0.55) KDM4ETSHRALDH1A1NPC1HPGD
SCHEMBL17397082 0.79 PIK3CD (0.42) PIK3CDPIK3CBPIK3CAKDM4EBRD4
SCHEMBL17397181 0.78 KDM4E (0.39) KDM4EBRD4ALDH1A1NPC1HPGD
SCHEMBL17397203 0.77 MAPT (0.44) PIK3CDKDM4EBRD4TSHRALDH1A1
SCHEMBL25212203 0.76 PIK3CD (0.43) PIK3CDPIK3CBPIK3CAKDM4EBRD4
SCHEMBL17397077 0.74 PIK3CD (0.55) PIK3CDPIK3CBPIK3CAKDM4EBRD4
SCHEMBL17397079 0.73 PIK3CD (0.42) PIK3CDPIK3CBPIK3CAMAPTMEN1
SCHEMBL10361997 0.71 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
EP-3164400-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS Lupin Limited (IN) 2017-05-10 EP disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS PIK3R5, PIK3R1, PIK3R4 PIK3CD 5/4885PIK3CB 14/4885PIK3CA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.